Stingray Healthcare, a European company dedicated to the treatment of cancer, has finalised a partnership with the Andrée Dutreix Institute (the “Institute”) in Dunkirk, one of the main integrated private cancer centres on the North Coast (Littoral Nord) and Maritime Flanders. This transaction is Stingray Healthcare’s second investment in France in just a year.
The Institute provides high-quality radiotherapy treatments to over 800 patients per year in the Pas-de-Calais and Nord departments. In addition, it offers oncology consultations and chemotherapy treatments in the region. Since taking over the Institute in 2013, the four current shareholding doctors have significantly improved the quality of care for patients through continuous investment in modern radiotherapy equipment.
Through its unique model of association, Stingray Healthcare is pleased to partner with the four independent practitioners of the Institute – who reinvest alongside Stingray Healthcare and remain shareholders – to ensure continuity of high-quality treatments for patients over the long-term.
This partnership with the Institute strengthens Stingray Healthcare’s presence in France following the investment in the Centre Catalan d’Oncologie (“CCO”) in January 2020. CCO is one of the largest private radiotherapy centres in the South West of France, treating nearly 2,000 new radiotherapy patients per year.
Stingray Healthcare, owned by Telemos Capital, has the ambition to become the independent European leader in radiotherapy and is therefore continuously looking for new partnerships with leading medical teams, in particularly in France and Germany.
Note: Stingray Healthcare at the time was called MedEuropa, prior to rebranding in September 2022.
